Adaptive Biotechnologies Corp
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue | $170,276 | $185,308 | $154,344 |
| Operating expenses | |||
| Cost of revenue | 75,553 | 57,909 | 49,301 |
| Research and development | 122,117 | 141,756 | 142,343 |
| Sales and marketing | 88,579 | 95,603 | 95,465 |
| General and administrative | 83,934 | 88,527 | 74,502 |
| Amortization of intangible assets | 1,699 | 1,699 | 1,699 |
| Impairment of right-of-use and related long-lived assets | 25,429 | — | — |
| Total operating expenses | 397,311 | 385,494 | 363,310 |
| Loss from operations | (227,035) | (200,186) | (208,966) |
| Interest and other income, net | 15,531 | 4,056 | 1,668 |
| Interest expense | (13,800) | (4,238) | — |
| Net loss | (225,304) | (200,368) | (207,298) |
| Add: Net loss attributable to noncontrolling interest | 54 | 177 | 19 |
| Net loss attributable to Adaptive Biotechnologies Corporation | $(225,250) | $(200,191) | $(207,279) |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | $(1.56) | $(1.40) | $(1.48) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | 144,383,294 | 142,515,917 | 140,354,915 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.